Drugs / acetylsalicylic acid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01163630 | Jun → Sep 2010 | — | AstraZeneca | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2016-03-23 | AstraZeneca | Results AstraZeneca reports top-line results from the Brilinta SOCRATES trial in stroke astrazeneca.com ↗
Fewer events were observed on Brilinta/Brilique versus the comparator in the overall trial population but the trend did not reach statistical significance. |
| 2011-08-02 | AstraZeneca | Regulatory Positive agreement received for approval of AXANUM (low-dose ASA/esomeprazole) in Europe astrazeneca.com ↗
Tuesday, 2 August 2011 AstraZeneca today announced that AXANUM, a fixed dose combination of 81 mg low-dose ASA (acetylsalicylic acid) and 20 mg esomeprazole, has received positive agreement for approval in 23 European Union member countries and in Norway. |
| 2010-06-04 | AstraZeneca | Regulatory AstraZeneca Submits Marketing Authorisation Application To European Union For Cardiovascular Drug Axanum astrazeneca.com ↗ |
| 2010-06-01 | AstraZeneca | Regulatory AstraZeneca Receives FDA Complete Response Letter for AXANUM New Drug Application astrazeneca.com ↗
Tuesday, 1 June 2010 AstraZeneca has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the new drug application for AXANUM (aspirin/esomeprazole magnesium) tablets. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2016-03-23 | AstraZeneca | AstraZeneca reports top-line results from the Brilinta SOCRATES trial in stroke astrazeneca.com ↗ |
| 2011-08-02 | AstraZeneca | Positive agreement received for approval of AXANUM (low-dose ASA/esomeprazole) in Europe astrazeneca.com ↗ |
| 2010-06-04 | AstraZeneca | AstraZeneca Submits Marketing Authorisation Application To European Union For Cardiovascular Drug Axanum astrazeneca.com ↗ |
| 2010-06-01 | AstraZeneca | AstraZeneca Receives FDA Complete Response Letter for AXANUM New Drug Application astrazeneca.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | acetylsalicylic acid | “acetylsalicylic acid (ASA)” NCT01163630 ↗ |
| Known as | ASA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01163630 ↗ |
| Route | Oral | “esomeprazole 20 mg/ASA 81 mg oral capsule” NCT01163630 ↗ |